Results 111 to 120 of about 14,888,290 (302)

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Plasmapheresis for Spur Cell Anemia in a Patient with Alcoholic Liver Cirrhosis

open access: yesCase Reports in Hematology, 2018
Background. Spur cell anemia (SCA) is a cause of hemolytic anemia in patients with alcoholic liver cirrhosis. Because dyslipidemia is related to the development of spur cells, SCA was previously treated with plasmapheresis. Case Report.
Kenji Miki   +2 more
doaj   +1 more source

Development of knowledge based parametric CAD modeling system for spur gear: An approach

open access: yesAlexandria Engineering Journal, 2018
In almost every mechanism, gears are extensively used machine parts to transmit power from one shaft to other with or without change of speed or direction.
E. Jayakiran Reddy, V. Pandu Rangadu
doaj   +1 more source

IDB News: Vol. 2. no. 9, October 1975

open access: yes, 1975
IDB News is a monthly publication of the Inter-American Development Bank and appears in English and Spanish ...
Inter-American Development Bank
core   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket   +14 more
wiley   +1 more source

IDB News: Vol. 2, no. 11, December 1975

open access: yes, 1975
IDB News is a monthly publication of the Inter-American Development Bank and appears in English and Spanish ...
Inter-American Development Bank
core   +1 more source

Early Clinical, Imaging, and Pathological Characteristics of SRPK3/TTN‐Digenic Myopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SRPK3/TTN‐digenic myopathy was recently established as a skeletal muscle myopathy caused by digenic inheritance. This study characterizes the early clinical presentation of SRPK3/TTN‐digenic myopathy in one previously reported and seven newly identified pediatric patients.
Rotem Orbach   +23 more
wiley   +1 more source

IDB News: Vol. 3, no. 4, May 1976

open access: yes, 1976
IDB News is a monthly publication of the Inter-American Development Bank and appears in English and Spanish ...
Inter-American Development Bank
core   +1 more source

IDB News: Vol. 1, no. 9, October 1974 [PDF]

open access: yes, 1974
IDB News is a monthly publication of the Inter-American Development Bank and appears in English and Spanish ...
Inter-American Development Bank
core   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy